Although much promising data that
interleukin (IL)-12 could be a powerful therapeutic agent against
cancer were reported in animal models, its excessive toxicity has become a problem for its clinical application.
IL-27 is a novel
IL-12 family member that plays a role in the early regulation of T helper cell 1 initiation, including induction of T-bet and
IL-12 receptor beta 2 expression. In the present study, we have evaluated the antitumor activity of
IL-27 against a murine
tumor model of colon
carcinoma C26. C26 cells, which were transduced with the single-chain
IL-27 cDNA and became secreting
IL-27 (C26-IL-27), exhibited minimal
tumor growth in vivo, and all of the mice inoculated with these cells survived healthily with complete
tumor remission. Inoculation of mice with C26-IL-27 induced enhanced IFN-gamma production and cytotoxic T-lymphocyte activity against C26
tumor in spleen cells. Recovered mice from the inoculation showed a
tumor-specific protective immunity to the following challenge with parental C26
tumor. The antitumor activity of
IL-27 was almost diminished in nude mice, and depletion of CD8(+) T cells and neutralization of IFN-gamma in immunocompetent mice reduced greatly the antitumor activity. Moreover, the antitumor activity was abolished in T-bet-deficient mice, whereas it was observed unexpectedly in mice deficient of signal transducer and activator of transcription (STAT) 4. These results suggest that
IL-27 has potent abilities to induce
tumor-specific antitumor activity and protective immunity and that the antitumor activity is mediated mainly through CD8(+) T cells, IFN-gamma, and T-bet but not through STAT4.